The initial reporter received questionable elecsys anti-sars-cov-2 results for 1 positive covid-19 patient on a cobas 6000 e601 module, serial number (b)(4).On (b)(6) 2020, the patient sample produced a positive result of 1.08 coi using the elecsys anti-sars-cov-2 method.The sample was retested on a different analyzer using the same method.The sample produced another positive result of 1.48 coi.The same sample was tested using the euroimmun iga-assay and produced a negative result of 0.43 coi.The same sample was tested using the euroimmun igg-assay and produced a negative result of 0.34 coi.The same sample was also tested using the diasorin igg-assay and the sample produced a result of < 0.43 coi.The results were not reported outside of the laboratory.It is unknown which results are believed to be correct.
|
The customer's sample was returned for investigation.The customer's result for the sample was reproducible with the elecsys anti-sars-cov-2 assay.Additional measurements were performed with a rapid assay from creative diagnostics as well as an independent in-house roche assay detecting other antibodies against sars-cov-2.A weak igm reactivity was detected in the rapid assay, whereas igg resulted non-reactive.Similarly, the roche in-house assay showed weak reactivity, however, below the cutoff level.Based on the available data, a general reagent issue could be excluded.The investigation did not identify a product problem.The cause of the event could not be determined.
|